GAITHERSBURG, Md., Oct. 22, 2024 (GLOBE NEWSWIRE) -- BullFrog AI, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced its VP Artificial Intelligence, Enrique García-Rivera, Ph.D., will present at Google’s inaugural Cancer AI... Read More

GAITHERSBURG, Md., Oct. 21, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("Bullfrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, announced today it has closed its previously announced definitive agreement for the purchase and sale of an aggregate of... Read More

GAITHERSBURG, Md., Oct. 18, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("Bullfrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, announced today it has entered into a definitive agreement for the purchase and sale of an aggregate of 1,565,000 shares... Read More

GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- BullFrog AI, Inc . (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the appointment of John Baldoni, Ph.D., to its Scientific Advisory Board. Dr. Baldoni brings over four decades... Read More

The study, led by Dr. Lopa Mishra and published in Cell Reports, provides new mechanistic evidence for role of BF-114 target β2-spectrin in obesity, MASLD, MASH, and HCC The findings suggest that targeting β2-spectrin with BF-114 can prevent the progression of liver diseases New data builds on earlier studies and further supports BF-114’s potential to address major unmet needs in treating obesity-related liver diseases Dr.... Read More

GAITHERSBURG, Md., Aug. 26, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a leader in AI-driven drug discovery, announced today that the Company will participate in the H.C. Wainwright 26th Annual Global Investment Conference being held in New York City. Interested parties may access live and archived webcasts of these events on the company’s investor relations... Read More

GAITHERSBURG, Md., July 25, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a leader in AI-driven drug discovery, announced significant advancements in its ongoing collaboration with the Lieber Institute for Brain Development (LIBD). Building on the progress detailed in our May 16, 2024 release, our research has now pinpointed specific molecular pathways associated... Read More

GAITHERSBURG, Md., May 29, 2024 (GLOBE NEWSWIRE) -- BullFrog AI, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, is pleased to invite investors to a webinar on June 12, 2024, at 4:15 p.m. ET. To register for the free webinar, please click... Read More

GAITHERSBURG, Md., May 16, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug discovery company using artificial intelligence (AI) and machine learning to enable the successful discovery and development of pharmaceuticals and biologics, today announced significant advancements in its collaboration with the Lieber Institute for Brain... Read More

GAITHERSBURG, Md., April 09, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that its Chief Scientific Officer (CSO), Tom Chittenden, will be presenting at the Quantum Computing... Read More

GAITHERSBURG, Md., March 08, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the availability of the recording for the recently held fireside chat. This enlightening session,... Read More

GAITHERSBURG, Md., Feb. 26, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the appointment of Dr. Thomas W. Chittenden, PhD, DPhil, PStat, as its new Chief Scientific Officer.... Read More

GAITHERSBURG, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) (“BullFrog AI” or the “Company”), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, announced February 21, 2024, the Underwriter’s decision to exercise their over-allotment option to purchase 218,382... Read More

GAITHERSBURG, Md., Feb. 09, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced its CEO, Vin Singh, alongside distinguished guest, Daniel R. Weinberger, M.D., Director and CEO of the... Read More

GAITHERSBURG, Md., Feb. 05, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, announced today the closing of an underwritten public offering of an aggregate of 1,507,139 shares of common stock (or... Read More

JERSEY CITY, N.J. , Feb. 1, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) a technology-enabled drug development company using (AI) and machine learning to enable the successful development of pharmaceuticals and biologics priced an underwritten public offering of an aggregate of... Read More

GAITHERSBURG, Md., Feb. 01, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("Bullfrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, announced today the pricing of an underwritten public offering of an aggregate of 1,507,139 shares of common stock (or... Read More

GAITHERSBURG, Md., Jan. 26, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. ( NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the appointment of two distinguished scientific advisors to its advisory board: Gwenn S. Smith, PhD,... Read More

GAITHERSBURG, Md., Jan. 17, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) (“BullFrog AI” or the “Company”), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced early results from its collaboration with the Lieber Institute for Brain Development (LIBD) that could... Read More

GAITHERSBURG, Md., Jan. 16, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that the Australian Patent Office has issued Patent No. 2019216757 protecting the Company’s novel... Read More

GAITHERSBURG, Md., Jan. 11, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that Vin Singh, Chief Executive Officer of BullFrog AI, will present at the Webull LIVE! Healthcare... Read More

GAITHERSBURG, Md., Dec. 29, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, issued a letter to shareholders from its CEO Vin Singh. Dear Fellow Shareholders, Firstly, I am deeply grateful for... Read More

The market for obesity drugs is projected to exceed $77 billion by 2030 Dr. Randy Seeley, a recognized expert on novel treatments for obesity, to lead study GAITHERSBURG, Md., Dec. 06, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful... Read More

GAITHERSBURG, Md., Oct. 18, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that Vin Singh, Founder and CEO of BullFrog AI, will present during Benzinga's All Access investor... Read More

Discoveries generated by analyzing The Cancer Genome Atlas using proprietary bfLEAP™ platform Target validation will be conducted through partnership with J. Craig Venter Institute (JCVI), a world-leading institution in genomics research and innovation GAITHERSBURG, Md., Oct. 05, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development... Read More

GAITHERSBURG, Md., Sept. 26, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced positive data in a preclinical study investigating the anti-cancer activity of a novel prodrug of... Read More

GAITHERSBURG, Md., Sept. 25, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that its founder and CEO Vin Singh will give a presentation at BioFuture 2023 (Oct. 4-6, 2023) on the... Read More

GAITHERSBURG, Md., Sept. 20, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the launch of BullFrog Data Networks, a purpose-built, comprehensive data network platform that... Read More

GAITHERSBURG, Md., Sept. 14, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that its founder and CEO Vin Singh will give a virtual presentation as part of Maxim Group’s 2023... Read More

GAITHERSBURG, Md., Sept. 13, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced a three-year global strategic partnership with the Lieber Institute for Brain Development (LIBD), a... Read More

GAITHERSBURG, Md., Sept. 07, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that its founder and CEO Vin Singh will give a webinar presentation on the Company’s use of machine... Read More

GAITHERSBURG, Md., Aug. 23, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a precision medicine company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that its machine learning/artificial intelligence technology, exclusively licensed from the Johns Hopkins University... Read More

GAITHERSBURG, Md., July 25, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a precision medicine company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that the United States Patent and Trademark Office (USPTO) will, on August 1, 2023, issue U.S. Patent No. 11,712,435... Read More

GAITHERSBURG, Md., July 11, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a precision medicine company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the appointment of Enrique García-Rivera, Ph.D., as its new Vice President of Artificial Intelligence. The appointment... Read More

GAITHERSBURG, Md., June 09, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("BullFrog AI" or the "Company"), a precision medicine company using AI and machine learning to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development, today announced its CEO Vin Singh will present at the Gujarati Physicians Convention in... Read More

GAITHERSBURG, Md., June 07, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("BullFrog AI" or the "Company"), a digital technology company using machine learning to usher in a new era of precision medicine, today announced the appointment of Toby Sayre, MS as VP of Business Development. Sayre brings more than 18 years of experience in life sciences and biotechnology consulting, business development,... Read More

GAITHERSBURG, Md., June 05, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("BullFrog AI" or the "Company"), a digital technology company using machine learning to usher in a new era of precision medicine, today announced the expansion of its worldwide license agreement with the Johns Hopkins Applied Physics Laboratory (APL), in Laurel, Maryland, for use of patented technology powering the Company’s... Read More

GAITHERSBURG, Md., May 26, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("BullFrog AI" or the "Company"), a digital technology company using machine learning to usher in a new era of precision medicine, today announced it filed its Form 10-Q with the Securities and Exchange Commission (“SEC”) for the quarter ended March 31, 2023. BullFrog AI received notice from Nasdaq on May 23, 2023, notifying... Read More

GAITHERSBURG, Md., May 15, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc . (NASDAQ:BFRG; BFRGW) ("BullFrog AI" or the "Company"), a digital technology company using machine learning to usher in a new era of precision medicine, today announced that Vin Singh, Chief Executive Officer, will present at the JMP Securities Life Sciences Conference on Monday, May 15, 2023 at 3:30 PM ET. A live webcast of the presentation will... Read More

GAITHERSBURG, Md., May 03, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("BullFrog AI" or the "Company"), a digital technology company using machine learning to usher in a new era of precision medicine, today announced that Vin Singh, Chief Executive Officer, will participate in a panel discussion titled "Best Practices and Key Considerations for Successful Deals" at the Pharma Partnering Summit... Read More

GAITHERSBURG, Md., April 25, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("BullFrog AI" or the "Company"), a digital technology company using machine learning to usher in a new era of precision medicine, today announced it filed its Form 10-K with the Securities and Exchange Commission (“SEC”) for its year ended December 31, 2022. "While our 10-K largely mirrored the S-1 we filed for our IPO, the... Read More

GAITHERSBURG, Md., April 20, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("BullFrog AI" or the "Company"), a digital technology company using machine learning to usher in a new era of precision medicine, today announced a strategic partnership with the Sage Group ( www.sagehealthcare.com ), a leader in the provision of strategic and transactional advice to healthcare and life science companies in... Read More

GAITHERSBURG, Md., April 18, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (Nasdaq: BFRG) ("Bullfrog AI" or the "Company"), a digital technology company using machine learning to usher in a new era of precision medicine, today announced an exclusive license agreement with Johns Hopkins University for prodrug compositions of mebendazole. The exclusive license was signed on October 13, 2022. The world-wide,... Read More

GAITHERSBURG, Md., April 13, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (Nasdaq: BFRG; BFRGW) ("Bullfrog AI" or the "Company"), a digital technology company using machine learning to usher in a new era of precision medicine, announced its Founder and CEO, Vin Singh, will participate in a panel discussion at the Money Show, taking place at the Paris Las Vegas Hotel & Casino April 24-26, 2023. Investors will have two... Read More

GAITHERSBURG, Md., April 06, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (Nasdaq: BFRG; BFRGW) ("Bullfrog AI" or the "Company"), a digital technology company using machine learning to usher in a new era of precision medicine, is pleased to announce its CEO, Vin Singh, will be featured on The RedChip Money Report ® on Bloomberg TV, this Saturday, April 8, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an... Read More

GAITHERSBURG, Md., April 04, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (Nasdaq: BFRG; BFRGW) ("Bullfrog AI" or the "Company"), a digital technology company using machine learning to usher in a new era of precision medicine, is pleased to announce its worldwide license agreement with Johns Hopkins University Applied Physics Laboratory (“APL”) for use of patented technology powering the Company’s bfLEAP™ platform.... Read More

GAITHERSBURG, Md., March 21, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("Bullfrog AI" or the "Company"), a digital technology company using machine learning to usher in a new era of precision medicine, is pleased to announce it is now featured on the new Webull Corporate Communication services platform. The BullFrog AI portal on the Webull platform will help provide the Company with a direct... Read More